About EAM 2201
This research proposes that K2's high adverse impact incidence is due, not less than in part, to distinct JWH-018 metabolite action within the cannabinoid one receptor (CB1R), and suggests that metabolites of most medicines, but not the carboxy metabolite, retain in vitro and in vivo activity at CB1Rs.Framework characterisation of urinary metabolit